Equitable Holdings Inc. Common Stock vs Guardant Health Inc. Common Stock — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.42B), while Guardant Health Inc. Common Stock trades at $162.8 (market cap $21.88B). The key difference: Guardant Health Inc. Common Stock is the larger of the two by market cap, and Equitable Holdings Inc. Common Stock pays a 2.16% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and Guardant Health Inc. Common Stock for 3 Days on average.
| EQH | GH | |
|---|---|---|
Market Cap | $14.42B | $21.88B |
Volume | 2,107,298 | 1,278,798 |
Sector | Financials | Health |
52-Week High | $54.50 | $187.22 |
52-Week Low | $35.34 | $64.19 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $5.48B | $22.52B |
Dividend Yield | 2.16% | — |
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →